Brinker Capital Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Brinker Capital Investments’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,820	Closed	-$262K	–	1989
2025 Q1	$262K	Buy	+10,820	New	+$244K	﹤0.01%	1685
2024 Q4	–	Sell	-13,212	Closed	-$263K	–	1838
2024 Q3	$263K	Sell	13,212 -80	-0.6%	-$1.48K	﹤0.01%	1588
2024 Q2	$206K	Sell	13,292 -190	-1%	-$2.96K	﹤0.01%	1630
2024 Q1	$215K	Buy	13,482 +3,199	+31%	+$48.2K	﹤0.01%	1587
2023 Q4	$155K	Sell	10,283 -2,645	-20%	-$36.2K	﹤0.01%	1603
2023 Q3	$151K	Sell	12,928 -886	-6%	-$11.9K	﹤0.01%	1571
2023 Q2	$186K	Buy	13,814 +3,155	+30%	+$45.4K	﹤0.01%	1563
2023 Q1	$177K	Buy	+10,659	New	+$176K	﹤0.01%	1506

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brinker Capital Investments's CPRX Position: Q2 2025 in Review

Brinker Capital Investments sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 10,820 shares — an estimated $262K sold.

Brinker Capital Investments first reported a position in CPRX in Q1 2023 and held it in 8 quarters. The position peaked at $263K in Q3 2024. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

Brinker Capital Investments reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Brinker Capital Investments sold 10,820 Catalyst Pharmaceutical shares in Q2 2025, an estimated $262K.
Brinker Capital Investments first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 8 quarters.
Brinker Capital Investments's Catalyst Pharmaceutical position peaked at $263K in Q3 2024.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Brinker Capital Investments's 13F filing for Q2 2025, filed 14 Aug 2025.